Back to top

A Phase I study that evaluated whether a gel containing dapivirine is safe for use in the rectum. The study, which enrolled 28 HIV-negative cisgender and transgender men and women at sites in Thailand and the U.S., will help determine whether further testing on the safety and acceptability of dapivirine gel as a potential rectal microbicide can be conducted in a larger population. Results are anticipated in mid-2020.

 

MTN-026 Backgrounder

30-October-2017

 

MTN-026 Q&A

30-October-2017

 

See Also

MTN-026 Protocol

 

MTN-026 Study Page

 

Rectal Microbicides - Fact Sheet

21-Apr-2020